Novo Nordisk: Approval within reach
The Danish biopharmaceutical giant is primarily associated with diabetes and weight-loss products. However, Novo Nordisk is also active in adjacent therapeutic areas. The company now has legitimate hopes of an expanded approval for the treatment of hemophilia A and B.
Last week, Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had issued a positive opinion on Alhemo (concizumab). If the European Commission also gives the green light, which is expected, the drug may now be available for pediatric patients aged twelve years or older with severe hemophilia A and moderate or severe hemophilia B without inhibitors.
Alhemo is already used for routine bleeding prevention in hemophilia, but only with inhibitors. Without these inhibitors, administration via pen is possible, which, according to Novo Nordisk, represents an "effective and easy-to-use option for patients with hemophilia A and B without inhibitors."
Good news from Novo Nordisk, although it has only a limited impact on the company's share price. Much more important remain the developments surrounding the semaglutide-based products Ozempic and Wegovy, as well as the other promising candidates in the research pipeline, including amycretin.
In recent trading days, Novo Nordisk's share price has recovered and risen above the €60 mark. In the short term, the second-quarter figures on August 6 will determine the company's future direction. DER AKTIONÄR remains optimistic and considers the current share price to be highly attractive for a long-term investment horizon.
Note on conflicts of interest:
The board member and majority shareholder of the publisher Börsenmedien AG, Mr. Bernd Förtsch, has directly and indirectly entered into positions in the following financial instruments or derivatives related to them mentioned in the publication, which may benefit from any price development resulting from the publication: Novo Nordisk.
The author holds direct positions in the following financial instruments or derivatives related to them mentioned in the publication, which may benefit from any price developments resulting from the publication: Novo Nordisk.
deraktionaer.de
